NCT01329991View on ClinicalTrials.gov

Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Rheumatoid Arthritis
Interventions
DRUG

PLX5622

PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo

DRUG

Placebo

Matching placebo for PLX5622

Trial Locations (4)

16635

Altoona Center for Clinical research, Duncansville

36207

Pinnacle Research Group, Anniston

48910

Medical Practice of Justus Fiechtner, MD, Lansing

75231

Metroplex Clinical Research Center, Dallas

Sponsors

Lead Sponsor

Plexxikon
All Listed Sponsors
lead

Plexxikon

INDUSTRY

NCT01329991 - Phase 1b Study of PLX5622 in Rheumatoid Arthritis Patients Who Are Receiving Methotrexate | Biotech Hunter | Biotech Hunter